FMP
InVivo Therapeutics Holdings Corporation
NVIV
NASDAQ
Inactive Equity
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
0.321 USD
-0.1673 (-52.17%)
Historical Prices
From:
To:
About
ceo
Dr. Richard M. Toselli M.D.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
CIK
0001292519
ISIN
US46186M6057
CUSIP
46186M605
Address
One Kendall Square
Phone
617 863 5500
Country
US
Employee
6
IPO Date
Nov 15, 2010
Financial Statement
Earnings
NVIV Financial Summary
CIK
0001292519
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
46186M605
ISIN
US46186M6057
Country
US
Price
0.32
Beta
0.66
Volume Avg.
3.77M
Market Cap
995.92k
Shares
-
52-Week
0.22-2.4
DCF
16.46
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.1
P/B
-
Website
https://www.invivotherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NVIV News
InvestorPlace
Oct 7, 2022
Why Is InVivo Therapeutics (NVIV) Stock Down 34% Today?
Source: ra2 studio/Shutterstock InVivo Therapeutics (NASDAQ: NVIV ) stock is on the move Friday after the company reached a deal for a direct offering of its shares. The registered direct offering has InVivo Therapeutics agreeing to sell 523,810 shares of NVIV stock to a single institutional investor.
InvestorPlace
Sep 10, 2021
7 Biotech Stocks to Buy That Have Millionaire-Maker Potentia...
This sector is always a risky area to gamble in. If you have the stomach for it, however, these biotech stocks could see massive gains.
Business Wire
Sep 8, 2021
InVivo Therapeutics Announces 75% Target Enrollment Achieved...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designed
PennyStocks
Jul 20, 2021
3 Biotech Penny Stocks That You Need to Know About In 2021
Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Jul 14, 2021
Best Penny Stocks To Watch For July 2021
Penny Stocks For Your Watch List In July The post Best Penny Stocks To Watch For July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Pulse2
Jul 13, 2021
NVIV Stock Increases Over 36% Intraday: Why It Happened
The stock price of Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) increased by over 36% during intraday trading. This is why it happened.
Benzinga
Jul 13, 2021
InVivo Therapeutics Stock Moves Higher On FDA Acceptance Of ...
The FDA has accepted InVivo Therapeutics Holdings Corp's (NASDAQ: NVIV) preclinical module, which is one of three individual modules required for the Company's humanitarian device exemption (HDE) application for its Neuro-Spinal Scaffold implant. Acceptance of the module indicates that FDA has completed its review of this module of the HDE and has no outstanding questions.
Business Wire
Jul 6, 2021
InVivo Therapeutics Urges All Stockholders to Vote at the 20...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today reminded stockholders that their virtual Annual Meeting of Stockholders is scheduled for Friday, July 16, 2021 at 11 a.m., ET and called on stockholders to vote to ensure that a quorum is present to hold the meeting and that the Company's proxy proposals are passed. Stockholders hol
